Compare Stocks

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRMD CorMedix	$5.42 -0.4%	$4.01	$2.57 ▼ $7.00	$297.08M	1.86	533,550 shs	628,423 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRMD CorMedix	-0.37%	-15.18%	+41.51%	+66.26%	+12.33%

You’re invited: Biggest crypto event of 2024 (Ad)

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRMD CorMedix	1.4184 of 5 stars	3.5	0.0	0.0	0.0	3.1	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRMD CorMedix	3.00	Buy	$13.00	139.85% Upside

Current Analyst Ratings

Latest CRMD and HZD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/9/2024	CRMD CorMedix	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$19.00
4/9/2024	CRMD CorMedix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
3/13/2024	CRMD CorMedix	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
1/31/2024	CRMD CorMedix	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $14.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRMD CorMedix	$60K	4,951.35	N/A	N/A	$1.28 per share	4.23

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRMD CorMedix	-$46.34M	-$0.92	N/A	N/A	N/A	N/A	-72.31%	-63.97%	5/20/2024 (Estimated)

Latest CRMD and HZD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/12/2024	Q4 2023	CRMD CorMedix	-$0.21	-$0.26	-$0.05	-$0.26	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRMD CorMedix	N/A	6.97	6.78

Ownership

Institutional Ownership

Company	Institutional Ownership
CRMD CorMedix	34.18%

Insider Ownership

Company	Insider Ownership
CRMD CorMedix	3.60%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CRMD CorMedix	82	54.81 million	52.84 million	Optionable

CRMD and HZD Headlines

Source	Headline
	CorMedix Inc. (NASDAQ:CRMD) Short Interest Up 6.2% in March americanbankingnews.com - April 18 at 2:38 AM
	Short Interest in CorMedix Inc. (NASDAQ:CRMD) Increases By 6.2% marketbeat.com - April 16 at 12:23 PM
	Biotech on a Budget: 7 Stocks Under $10 With Huge Potential investorplace.com - April 15 at 12:54 PM
	CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin) globenewswire.com - April 15 at 8:30 AM
	CRMD Apr 2024 7.000 call finance.yahoo.com - April 15 at 12:28 AM
	CRMD Apr 2024 8.000 put finance.yahoo.com - April 15 at 12:28 AM
	Wall Street Analysts Predict a 146.21% Upside in CorMedix (CRMD): Here's What You Should Know zacks.com - April 11 at 10:55 AM
	CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference finance.yahoo.com - April 11 at 8:44 AM
	CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference globenewswire.com - April 11 at 8:30 AM
	CorMedix (NASDAQ:CRMD) Receives "Market Outperform" Rating from JMP Securities americanbankingnews.com - April 10 at 4:24 AM
	CorMedix (NASDAQ:CRMD) Receives "Buy" Rating from Needham & Company LLC americanbankingnews.com - April 10 at 4:24 AM
	CorMedix (NASDAQ:CRMD) Receives Market Outperform Rating from JMP Securities marketbeat.com - April 9 at 8:49 AM
	Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Shandong Weigao Group Medical Polymer Co (OtherSHWGF) and Cormedix (CRMD) markets.businessinsider.com - April 9 at 7:36 AM
	CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC globenewswire.com - April 8 at 8:30 AM
	Breakeven On The Horizon For CorMedix Inc. (NASDAQ:CRMD) finance.yahoo.com - April 2 at 12:24 PM
	CorMedix Inc. to Present at the Needham Annual Healthcare Conference finance.yahoo.com - March 27 at 9:34 AM
	CRMD Apr 2024 6.000 put finance.yahoo.com - March 16 at 9:19 AM
	CRMD Apr 2024 3.000 put finance.yahoo.com - March 16 at 8:46 AM
	CRMD Apr 2024 3.000 call finance.yahoo.com - March 16 at 8:16 AM
	CorMedix Inc. (NASDAQ:CRMD) CEO Joseph Todisco Purchases 13,561 Shares insidertrades.com - March 15 at 11:42 AM
	Truist Financial Reaffirms Their Buy Rating on Cormedix (CRMD) markets.businessinsider.com - March 13 at 8:41 PM
	Analysts Offer Insights on Healthcare Companies: Cencora (COR), Cormedix (CRMD) and NeueHealth Inc (NEUE) markets.businessinsider.com - March 13 at 1:26 PM
	CorMedix Inc. (NASDAQ:CRMD) Q4 2023 Earnings Call Transcript finance.yahoo.com - March 13 at 10:40 AM
	Ayr Wellness reports mixed Q4 results; initiates Q1 FY24 outlook seekingalpha.com - March 13 at 8:25 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

CorMedix

NASDAQ:CRMD

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial